Navigation Links
FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
Date:12/8/2010

FORT WORTH, Texas, Dec. 8, 2010 /PRNewswire/ -- Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL® Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey. DPT Laboratories is one of Healthpoint's contract manufacturers for the brand.

"The approval of this second production facility marks a significant milestone for the SANTYL® brand, allowing us to immediately double our manufacturing capacity for this important therapeutic agent," said Travis E. Baugh, President and Chief Operating Officer of Healthpoint. "The approval culminates a multi-year effort undertaken to ensure continuous, uninterrupted supply to the healthcare community of the only FDA-approved enzymatic debrider available in the United States."

About Collagenase SANTYL® Ointment

Collagenase SANTYL® Ointment is a selective enzymatic debriding agent that contains 250 collagenase units per gram of white petrolatum USP. It is indicated for debriding chronic dermal ulcers and severely burned areas.* The enzyme collagenase is derived from the fermentation by Clostridium histolyticum and possesses the ability to liquefy collagen in necrotic tissue.

*Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone. See complete prescribing information online at: http://www.santyl.com/prescribing.

About DPT Laboratories

DPT, a DFB Pharmaceuticals, Inc. affiliate company, is a contract development and manufacturing organization (CDMO) providing companies the best solutions to their sterile and non-sterile drug development and manufacturing needs through innovation, technology and service. Specializing in semi-solid and liquid dosage forms, DPT has a reputation for quality, unmatched technical expertise, extensive manufacturing capabilities and an exemplary regulatory compliance record. With five cGMP facilities, including R&D, manufacturing and packaging operations in San Antonio, Texas, and Lakewood, New Jersey, DPT offers full service outsourcing solutions. For more information, call 210-476-8100 or visit www.DPTLabs.com.

About HEALTHPOINT, Ltd.

Since 1992, HEALTHPOINT has been dedicated to innovative technologies for the prevention and treatment of acute, chronic and burn-related wounds. The company is presently focused on the research and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: Collagenase SANTYL® Ointment, OASIS® Wound Matrix and HYDROFERA BLUE® Bacteriostatic Wound Dressings. HEALTHPOINT is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. HEALTHPOINT is a DFB Pharmaceuticals, Inc. affiliate company, and is based in Fort Worth, Texas. For more information, visit the HEALTHPOINT website at www.healthpoint.com.

Healthpoint and design, SANTYL, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.

HYDROFERA BLUE is a registered trademark of Hydrofera, LLC.


'/>"/>
SOURCE Healthpoint
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
2. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
3. FDA Approves New Treatment Option for Late-Stage Breast Cancer
4. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
5. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
6. FDA Approves New Indication for Afinitor
7. FDA Approves Teflaro for Bacterial Infections
8. FDA Approves Latuda to Treat Schizophrenia in Adults
9. FDA Approves Additional Medical Indication for Sprycel
10. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
11. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits ... published by New Frontier Data, the legal cannabis market is projected ... legalization in the United States , as well ... a major factor that drives growth in this sector. Medical cannabis ...
(Date:3/28/2017)... 2017  Las Vegas ophthalmology practice, Center For Sight, ... (Allergan, Dublin ), an implant that ... reducing intraocular pressure in patients with moderate to severe ... by glaucoma that can lead to progressive optic nerve ... left untreated. According to the National Eye ...
(Date:3/28/2017)... LONDON , March 28, 2017 ... report,"Evolving Pharmaceutical Marketing Strategies: Digital as a Key ... of the changing pharmaceutical marketing landscape in the ... adopts new technologies to provide medical advancements, it ... its marketing efforts, mostly relying on traditional channels ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading ... of a free, public-facing tool for analyzing the costs of various drug regimens ... comparative information to patients, providers, insurers and pharmaceutical companies about the estimated costs ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... ... 2017 , ... Calibration, qualification, and the appropriate level of ... GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled “ ... requirements are explained. The challenge is to determine how to put the ...
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
Breaking Medicine News(10 mins):